Spots Global Cancer Trial Database for denosumab
Every month we try and update this database with for denosumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers | NCT01624766 | Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali... | Anakinra Denosumab Everolimus | 18 Years - | M.D. Anderson Cancer Center | |
| Denosumab for Smoldering Multiple Myeloma | NCT03839459 | Smoldering Mult... | Denosumab | 18 Years - | University of Rochester | |
| Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab | NCT00259740 | Relapsed or Pla... | DENOSUMAB | 18 Years - | Amgen | |
| Denosumab in Subjects With Giant Cell Rich Tumors of Bone | NCT03605199 | Aneurysmal Bone... Giant Cell Gran... Osteoblastoma Chondroblastoma Chondromyxoid F... | Denosumab | 18 Years - | Leiden University Medical Center | |
| Study of Denosumab in Subjects With Giant Cell Tumor of Bone | NCT00680992 | Cancer Giant Cell Tumo... Giant Cell Tumo... Benign Giant Ce... | Denosumab | 12 Years - | Amgen | |
| Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors | NCT05590949 | Breast Cancer | Physical Evalua... Dual-energy X-r... Trabecular Bone... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| PraG With RANKL Inhibitor for the Treatment of Advanced Multiple Metastatic Solid Tumors | NCT05435768 | Metastatic Soli... | Denosumab | 18 Years - | Second Affiliated Hospital of Soochow University | |
| Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only | NCT00950911 | Bone Metastases... Bone Metastases... Bone Metastases... | amg 162 | 18 Years - | Amgen | |
| Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease | NCT02101164 | Solid Tumor Metastatic Bone... | denosumab pamidronate | 18 Years - | Amgen | |
| Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults | NCT04798326 | Bone Tumor | MW032 Xgeva® | 18 Years - 65 Years | Mabwell (Shanghai) Bioscience Co., Ltd. | |
| Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases | NCT02758132 | Prostate Cancer | Denosumab Enzalutamide Abiraterone Prednisone | 18 Years - | University of Hawaii | |
| RANKL Inhibition and Mammographic Breast Density | NCT04067726 | Dense Breasts | Denosumab Placebo Calcium Vitamin D3 Core needle bio... Blood draw | 40 Years - | Washington University School of Medicine | |
| A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) | NCT04907851 | Advanced Solid ... | RXC004 RXC004 RXC004 Denosumab pembrolizumab | 18 Years - | Redx Pharma Plc | |
| Outcome of Dental Implant Therapy in Patients Treated With Antiresorptive Medication | NCT04741906 | Missing Teeth Implants Cancer Osteoporosis | Dental implant ... Prosthetic trea... | - | Copenhagen University Hospital at Herlev | |
| Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China | NCT03358212 | Giant Cell Tumo... | Denosumab | 16 Years - 50 Years | Peking University People's Hospital | |
| Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | NCT01077154 | Breast Cancer | Placebo Denosumab | 18 Years - | Amgen | |
| Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss | NCT00925600 | Cancer Cataract Low Bone Minera... Osteopenia Osteoporosis Prostate Cancer | Denosumab Placebo | 30 Years - 120 Years | Amgen | |
| Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation | NCT04711109 | BRCA1 Mutation Breast Cancer Breast Diseases Breast Neoplasm... Breast Carcinom... Neoplasms | Denosumab Placebo Quality-of-Life... | 25 Years - 55 Years | Alliance for Clinical Trials in Oncology | |
| Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma. | NCT00330759 | Bone Metastases | Denosumab Zoledronic Acid | 18 Years - | Amgen | |
| A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer | NCT01864798 | Breast Neoplasm... | Denosumab | 18 Years - | Jules Bordet Institute | |
| Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma | NCT03161756 | Melanoma Stage ... Melanoma Stage ... Melanoma | Denosumab Nivolumab Ipilimumab | 18 Years - | Melanoma and Skin Cancer Trials Limited | |
| Presurgical Trial of Denosumab in Breast Cancer | NCT02900469 | Breast Cancer | denosumab Surgery | 18 Years - | NYU Langone Health | |
| Outcome of Dental Implant Therapy in Patients Treated With Antiresorptive Medication | NCT04741906 | Missing Teeth Implants Cancer Osteoporosis | Dental implant ... Prosthetic trea... | - | Copenhagen University Hospital at Herlev | |
| Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors | NCT05590949 | Breast Cancer | Physical Evalua... Dual-energy X-r... Trabecular Bone... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only | NCT00950911 | Bone Metastases... Bone Metastases... Bone Metastases... | amg 162 | 18 Years - | Amgen | |
| Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer | NCT02366130 | Breast Cancer | Ra-223 dichlori... Denosumab Hormone Therapy | 18 Years - | M.D. Anderson Cancer Center | |
| Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 | NCT03301857 | Giant Cell Tumo... | Denosumab | - | Amgen | |
| Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer | NCT01545648 | Early Stage Bre... | Denosumab | 18 Years - | University of California, San Francisco | |
| Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer | NCT00321620 | Bone Metastases | zoledronic acid denosumab | 18 Years - | Amgen | |
| RANKL Inhibition and Breast Tissue Biomarkers | NCT03629717 | Breast Cancer P... Mammographic De... | Ultrasound-guid... Denosumab Blood draw Calcium Vitamin D | 35 Years - | Washington University School of Medicine | |
| Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy | NCT00556374 | Breast Cancer | Placebo Denosumab Non-steroidal a... Zoledronic Acid Standard of Car... | 45 Years - 100 Years | Amgen | |
| Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma. | NCT00330759 | Bone Metastases | Denosumab Zoledronic Acid | 18 Years - | Amgen | |
| Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer | NCT01545648 | Early Stage Bre... | Denosumab | 18 Years - | University of California, San Francisco | |
| Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease | NCT06314698 | Multiple Myelom... Bone Diseases | Narlumosbart Denosumab | 18 Years - | RenJi Hospital | |
| Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy | NCT02129699 | Lung Cancer Non... | Denosumab None, standard ... | 18 Years - | ETOP IBCSG Partners Foundation | |
| Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | NCT01077154 | Breast Cancer | Placebo Denosumab | 18 Years - | Amgen | |
| A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone | NCT05402865 | Giant Cell Tumo... | Denosumab | 18 Years - | Shanghai JMT-Bio Inc. | |
| Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab | NCT00259740 | Relapsed or Pla... | DENOSUMAB | 18 Years - | Amgen | |
| Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer | NCT00838201 | Cancer Carcinoma Castrate-Resist... Prostate Cancer Tumors | Denosumab | 18 Years - | Amgen | |
| Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors | NCT04812509 | Bone Metastases | MW032 Xgeva | 18 Years - | Mabwell (Shanghai) Bioscience Co., Ltd. | |
| Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer | NCT00838201 | Cancer Carcinoma Castrate-Resist... Prostate Cancer Tumors | Denosumab | 18 Years - | Amgen | |
| Study of Denosumab in Subjects With Giant Cell Tumor of Bone | NCT00680992 | Cancer Giant Cell Tumo... Giant Cell Tumo... Benign Giant Ce... | Denosumab | 12 Years - | Amgen | |
| Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer | NCT00286091 | Hormone Refract... | Denosumab Placebo | 18 Years - | Amgen | |
| RANKL Inhibition and Breast Tissue Biomarkers | NCT03629717 | Breast Cancer P... Mammographic De... | Ultrasound-guid... Denosumab Blood draw Calcium Vitamin D | 35 Years - | Washington University School of Medicine | |
| Denosumab for Breast Cancer With Bone Mets | NCT01952054 | Breast Cancer | Denosumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone | NCT05813665 | Giant Cell Tumo... | Narlumosbart Denosumab | 12 Years - | Shanghai JMT-Bio Inc. | |
| Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy | NCT03382574 | Ovarian Carcino... | Denosumab Salpingo-Oophor... | 18 Years - | National Cancer Institute (NCI) | |
| Denosumab as an add-on Neoadjuvant Treatment (GeparX) | NCT02682693 | Breast Cancer F... Tubular Breast ... Mucinous Breast... Invasive Ductal... HER2 Positive B... Inflammatory Br... Tubular Breast ... | Denosumab nab-Paclitaxel Epirubicin Cyclophosphamid... Carboplatin Trastuzumab Pertuzumab | 18 Years - 75 Years | German Breast Group | |
| Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases | NCT03520231 | Urothelial Carc... Kidney Cancer Ureter Cancer Bladder Cancer | Denosumab Denosumab Place... Gemcitabine Carboplatin Cisplatin Calcium Vitamin D | 18 Years - | University Health Network, Toronto | |
| Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer | NCT00838201 | Cancer Carcinoma Castrate-Resist... Prostate Cancer Tumors | Denosumab | 18 Years - | Amgen | |
| Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | NCT00896454 | Breast Cancer Hypercalcemia o... Colon Cancer Endocrine Cance... Head and Neck C... Kidney Cancer Lung Cancer Lymphoma Metastatic Canc... Multiple Myelom... Parathyroid Neo... Renal Cancer Thyroid Cancer Hodgkin's Lymph... Non-Hodgkin's L... Non-Small Cell ... | denosumab | 18 Years - | Amgen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
